S. Korea Ministry Denies Bayer Schering Label Of Ineptitude In R&D Plans
This article was originally published in PharmAsia News
Executive Summary
South Korea's Health Ministry denies it blundered and lost out as the site of Bayer Schering Pharma's research and development center to be built instead in China. The firm's Asia-Pacific chief, Chris Lee, had told South Korean reporters the country lost because of government ineptitude, including misdirected or unanswered telephone calls while the company was considering South Korea as the site. But the Ministry of Health, Welfare and Family Affairs said it was never contacted by Bayer Schering about such a move. Since that denial, the company has declined to comment, claiming business confidentiality. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.